Part-Time

Field & Infusion Nurse

RPN/LPN

Updated on 8/28/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Moncton, NB, Canada

In Person

Travel within the designated IBU and surrounding IBUs is required.

Bachelor's

Category
Medical, Clinical & Veterinary (1)
Required Skills
CPR
Nursing
PALS
ACLS
Patient Education

Get referred to Cencora

See people who can refer or advise you

Requirements
  • A diploma or university degree in nursing or a related field is required.
  • A minimum of two years of experience as a Registered Practical Nurse or Licensed Practical Nurse is required.
  • Current registration with the provincial licensing body and a current CPR certificate are required.
  • Experience in an acute-care inpatient or outpatient setting or a homecare setting is required.
  • The candidate must be able to use a cell phone and fax machine for making and confirming appointments and assignments.
  • The candidate must be able to work autonomously with little supervision as part of a larger team.
  • The candidate must hold and maintain a valid, non-expired, unrestricted driver's license and insurance coverage.
  • The candidate must be able to travel to clinics and homecare appointments within a set geographical boundary.
  • The candidate must follow nursing and clinic standard operating procedures, work instructions, provincial health and safety requirements, professional nursing standards, regulatory requirements, and company policies and procedures.
  • The candidate must complete ongoing and annual education training within the specified timeframes.
  • The candidate must be flexible enough to provide services for prescheduled and occasional last-minute patient appointment requests.
Responsibilities
  • Administer intramuscular, subcutaneous, and intravenous medications as applicable in home or specialty clinic settings.
  • Support and monitor intravenous infusion treatments in clinic and homecare settings.
  • Monitor post-injection and post-infusion treatments and chart and report activities according to program protocols and professional nursing documentation standards.
  • Provide patient education individually or in groups based on program protocols.
  • Report adverse events, serious adverse events, and product complaints according to Innomar training, policies, and procedures.
  • Provide reliable availability according to the employment agreement to meet the needs of the IBU and nursing and clinic key performance indicators.
  • Coordinate daily with patients, case managers, physicians, scheduling, and other departments to meet timelines for appointments, treatments, and information communication.
  • Perform administrative duties including monthly clinic audits and supply ordering.
  • Participate in team web-based meetings and training sessions with the Business Area Manager, Registered Nurse Educator, and Nurse Champion.
  • Participate in specialized client-related training as required.
  • Consult with physicians and pharmaceutical and biotechnology clients regarding education and implementation of product-specific programs.
  • Travel within the designated IBU and surrounding IBUs to meet operational needs.
  • Perform related duties and tasks as required by Innomar.
  • Remain on standby or on call when required to meet service needs.
Desired Qualifications
  • Experience with intravenous therapy is an asset.
  • Advanced Cardiovascular Life Support, Pediatric Advanced Life Support, multiple sclerosis, and CVAA certifications are considered assets.
  • Experience with central venous lines and ports is considered an asset.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026: Cencora raised fiscal 2026 EPS guidance to $17.75-$17.95.
  • July 31, 2026: Cencora expanded its revolver to $7 billion, extending maturity to 2031.
  • Cencora completed $1 billion in share repurchases during Q3, reducing diluted shares to 194 million.

What critics are saying

  • Baltimore dropped its opioid case after Maryland's April 2026 ruling vacated Cencora's $152 million verdict.
  • Cencora directors still face a $111.3 million opioid settlement, confirming persistent litigation over legacy conduct.
  • A California labor class action and heavy debt coverage pressure threaten margins before fiscal 2027.

What makes Cencora unique

  • Cencora's specialty platform, including OneOncology and RCA MSOs, drives outsized growth on August 5, 2026.
  • Nucleus inventory tools embed Cencora inside specialty physician practices' workflows across 20+ sites.
  • Global distribution plus World Courier and European 3PL give Cencora reach beyond U.S. drug flow.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.

Yahoo Finance
Jul 13th, 2026
CVS Health leads Q1 health insurance earnings as Cencora misses revenue estimates by 3.9%

CVS Health led health insurance providers in Q1, with revenues of $100.4 billion, up 6.2% year on year and beating analyst expectations by 6.3%. The company exceeded full-year EPS guidance estimates. The 12 health insurance provider stocks tracked reported strong Q1 results overall. Revenues beat consensus estimates by 1.4%, whilst next quarter's guidance was in line. Share prices rose 37.4% on average following the earnings announcements. Cencora performed weakest amongst peers, reporting revenues of $78.36 billion, up 3.8% year on year. This fell short of analyst expectations by 3.9%. The stock has remained flat since reporting and currently trades at $303.53. The industry faces tailwinds from an ageing population and improved data analytics, but regulatory scrutiny on pricing and medical cost inflation may impact margins.